Quick Update for Novavax (NVAX) Investors

By Harris Dyer • Wednesday, October 04 12:12 • Permanent Link

Novavax sank -7.2% today, compared to the S&P 500's day change of 1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Novavax has moved -62.0% over the last year, and the S&P 500 logged a change of 13.0%
NVAX has an average analyst rating of hold and is -65.44% away from its mean target price of $20.6 per share
Its trailing earnings per share (EPS) is $-7.22
Novavax has a trailing 12 month Price to Earnings (P/E) ratio of -1.0 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.21 and its forward P/E ratio is -5.9
Novavax is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-273240640, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.